At SynBioBeta 2026, cell stability engineering was presented: AI mapping of aging and proteostasis editing for treating age-related diseases. Learn the details of the breakthrough.
The Japanese market is shifting from anti-age to reverse-age: epigenetics, exosomes, and senolytics. Find out who is winning the multi-billion dollar race for rejuvenation. Read the analysis.
Breakthrough in oncology: how nanoparticles and CRISPR epigenome editing reverse tumor resistance to chemotherapy. Learn about clinical successes in 2026.
Learn about the first clinical trial of ER-100 cell rejuvenation therapy from Life Biosciences. How epigenetic reprogramming can reverse aging. Read details.
Analysis of the clinical study of the antioxidant MitoQ and the epigenetic clock LinAge3: who benefits from the race for biological rejuvenation and what are the hidden risks. Learn the details.
How the SHARP clinical study with 1500 participants attempts to prove that biological aging can be slowed. Learn who will benefit from the validation of epigenetic clocks.
Nature review of new life extension strategies: senolytics, senomorphics, and epigenetic rejuvenation. Key findings, timeline, and market winners. Read details.
Senolytic drugs D+Q reduced biological age in humans for the first time. Learn how removing old cells rejuvenates the body. Read details of the breakthrough.
From the web
Google
https://www.google.be/index.html
Search the world's information, including webpages, images, videos and more. Google has many special features to help you find …